Wang Xiuyun, Huang Zongqiong, Li Hong, Cai Xuebin
Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R.China.
Zhongguo Fei Ai Za Zhi. 2007 Jun 20;10(3):234-6. doi: 10.3779/j.issn.1009-3419.2007.03.17.
About 80% lung cancer is non-small cell lung cancer (NSCLC) and 70%-80% are in advanced stage. Chemotherapy is main treatment method. The aim of this study is to compare the therapeutic effects and toxicity of NP regimen combined with Shenqifuzheng injection on elder patients with advanced NSCLC.
Totally 69 patients enrolled into this study and were randomized into two groups: treatment group (35 patients) and control group (34 patients). Each patient received NVB 25mg/m² intravenously at days 1 and 8 and DDP 30mg intravenously from 1st day to 4th day. Shenqifuzheng injection was used in the treatment group by 250mL per day for 10 days.
There was no significant difference of the response rate between two groups (45.7% vs 41.2%, P > 0.05). The hematological toxicity, nausea and vomiting in the treatment group were lower than those in the control group with significant difference (P < 0.05). The adverse effects were well tolerable.
NP regimen combined with Shenqifuzheng injection on elder patients with advanced NSCLC is effective and safe. Shenqifuzheng injection has definite toxicity relieving effect on treating elder patients with advanced NSCLC.
约80%的肺癌为非小细胞肺癌(NSCLC),其中70%-80%处于晚期。化疗是主要的治疗方法。本研究旨在比较NP方案联合参芪扶正注射液对老年晚期NSCLC患者的治疗效果及毒性。
共纳入69例患者,随机分为两组:治疗组(35例)和对照组(34例)。每位患者在第1天和第8天静脉滴注长春瑞滨25mg/m²,第1天至第4天静脉滴注顺铂30mg。治疗组使用参芪扶正注射液,每天250mL,共10天。
两组有效率无显著差异(45.7%对41.2%,P>0.05)。治疗组的血液学毒性、恶心呕吐低于对照组,差异有统计学意义(P<0.05)。不良反应耐受性良好。
NP方案联合参芪扶正注射液治疗老年晚期NSCLC患者有效且安全。参芪扶正注射液对老年晚期NSCLC患者有确切的减轻毒性作用。